We randomly assigned patients in a 2:1 ratio to receive treatment with an everolimus-eluting bioresorbable scaffold ( Absorb , Abbott Vascular , Santa Clara , CA , USA ) or treatment with an everolimus-eluting metallic stent ( Xience , Abbott Vascular , Santa Clara , CA , USA ) .